Anthony DiGiandomenico - 10 Oct 2025 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Reporting relationship: Director
Issuer ticker: NDRA
Reported as of: 10 Oct 2025
Net transaction value: +$1,500,010
SEC form: 4
Accepted by SEC: 15 Oct 2025, 21:54:17 UTC
Prior SEC filing: 01 Jul 2025
Next SEC filing: 23 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact

Key filing fact

Anthony DiGiandomenico filed Form 4 for ENDRA Life Sciences Inc. (NDRA) on 15 Oct 2025.

Key facts

This page summarizes Anthony DiGiandomenico's Form 4 filing for ENDRA Life Sciences Inc. (NDRA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Oct 2025, 21:54.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: +$1,500,010.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001083544 Primary reporting owner

DIGIANDOMENICO ANTHONY

Relationship: Director
Address: C/O ENDRA LIFE SCIENCES INC., 3600 GREEN COURT, SUITE 350, ANN ARBOR
Signature: /s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact
Signature date: 15 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NDRA transaction

Common Stock

Award

Transaction value: $500,003
Shares: +70,822
Change %: +1301%
Price: $7.06
Shares after: 76,265
Date: 10 Oct 2025
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NDRA transaction Derivative

Warrants

Award

Transaction value: $1,000,007
Shares: +141,644
Change %
Price: $7.06
Shares after: 141,644
Date: 10 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 141,644
Exercise price: $6.81
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

Footnote F2

Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock.

Footnote F3

Includes unvested restricted stock units.